Cumberland Pharmaceuticals Inc. Sees 37.4% Decline in Short Interest

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) has experienced a notable reduction in its short interest throughout February. By February 28th, the total short interest reached 313,600 shares, reflecting a substantial decrease of 37.4% from the previous total of 500,700 shares on February 13th. Currently, about 4.0% of the company's shares are sold short. Given the average daily trading volume of 3,190,000 shares, the short-interest ratio stands at a mere 0.1 days.

Analyst Upgrades and Downgrades

In a separate development, StockNews.com has upgraded Cumberland Pharmaceuticals' shares from a "hold" rating to a "buy" rating in a research report released on March 6th.

Cumberland Pharmaceuticals Stock Performance

On Friday, CPIX stock observed a slight decrease of $0.03, concluding the trading day at $5.46. During the session, 45,268 shares changed hands, below its average volume of 858,952 shares. The stock’s fifty-day simple moving average is $4.07, while the two-hundred-day simple moving average is $2.37. Cumberland Pharmaceuticals reports a debt-to-equity ratio of 0.41, a quick ratio of 0.99, and a current ratio of 1.13. Over the past year, the stock has reached a low of $1.04 and a high of $7.25. Its market capitalization stands at $76.67 million, with a price-to-earnings ratio recorded at -7.09 and a beta of -0.19.

Additionally, Cumberland Pharmaceuticals released its quarterly earnings results on March 4th. The specialty pharmaceutical company reported an earnings per share (EPS) of ($0.03) for the quarter, alongside revenue totaling $10.44 million. The firm recorded a negative return on equity of 9.50% and a negative net margin of 29.54%.

Institutional Inflows and Outflows

Recently, an institutional investor has increased its position in Cumberland Pharmaceuticals. Two Sigma Investments LP raised its stake in the company by 94.3% during the fourth quarter, according to a recent filing with the Securities and Exchange Commission. As a result, the fund acquired an additional 18,271 shares, bringing its total to 37,649 shares, which accounts for approximately 0.27% of Cumberland Pharmaceuticals' total stock valued at $89,000. Currently, 15.51% of the stock is held by institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of prescription products designed for hospital acute care, gastroenterology, and oncology both in the United States and internationally. The company provides various products, including Acetadote, an injection for acetaminophen overdose; Caldolor, an injectable solution for treating pain and fever; Kristalose, an oral solution for constipation; Omeclamox-Pak for Helicobacter pylori infection; Vaprisol, an injection for specific types of hyponatremia; Sancuso, an injection for chemotherapy-related symptoms; and Vibativ, an injection targeting serious bacterial infections, among others.

See Also

• Five stocks we like better than Cumberland Pharmaceuticals
• Health Care Stocks Explained: Why You Might Want to Invest
• Ignore Reports, Apple Won't Install Starlink with iOS 18.3
• 3 Warren Buffett Stocks to Buy Now
• Casey’s Uptrend Remains Strong—New Highs on the Horizon
• Best Stocks Under $10.00
• Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead

This news article is crafted to provide readers with prompt updates on financial data related to Cumberland Pharmaceuticals. For further inquiries, readers are encouraged to contact the editorial team.

Should You Invest $1,000 in Cumberland Pharmaceuticals Right Now?

Before making an investment decision regarding Cumberland Pharmaceuticals, it's essential to consider various factors.

Market analysts track investment insights daily, revealing stocks endorsed by top-rated research analysts. Currently, Cumberland Pharmaceuticals is recognized with a hold rating, but many analysts recommend other stocks as better investment choices.

For further insights, consider exploring leading stocks recommended by analysts.

Cumberland, Stocks, Pharmaceuticals, Investing, ShortInterest